FaceWise Consolidated Memory Assessment
An AI-administered memory assessment that uses name-to-face associative paradigms to detect subtle memory impairment in early dementia populations. Designed for the clinical trial populations where existing instruments lack the sensitivity to detect treatment-related change.
Assessment Design
Name-to-Face Associative Paradigm
Leverages the fundamental human cognitive task of associating names with faces. This paradigm engages episodic memory encoding and retrieval circuits that are among the earliest affected in Alzheimer's pathology.
AI-Administered
Fully automated administration removes rater variability, ensures standardized delivery across sites, and enables consistent assessment regardless of examiner experience or training level.
Sensitive to Early Change
Designed specifically for the clinical populations where existing instruments struggle most: subjective memory impairment, prodromal Alzheimer's disease, and early mild AD.
Longitudinal Tracking
Multiple parallel forms enable repeated administration without practice effects. Critical for clinical trials measuring treatment effects over extended periods.
Target Populations
FaceWise is being developed for the dementia spectrum where early detection and sensitive longitudinal measurement are most critical.
Subjective Memory Impairment
Individuals reporting memory concerns before objective impairment is detectable on standard instruments.
Prodromal Alzheimer's Disease
Patients with biomarker evidence of AD pathology and mild cognitive symptoms not yet meeting dementia criteria.
Early Mild Alzheimer's Disease
Recently diagnosed AD patients where treatment intervention has the highest potential for meaningful impact.
Moderate Alzheimer's Disease
Patients with established AD where sensitive endpoints are needed to detect stabilization or slowed decline.
Interested in FaceWise?
FaceWise is currently in development. Contact us to learn more about the assessment, discuss potential integration into your clinical program, or express interest in early access.
Get in Touch